The results of a nine-month investigation by health regulators in the European Union should be comforting for anyone taking Ozempic and other similar drugs to treat type 2 diabetes and/or obesity. EU officials said Friday that they failed to find evidence of a causative link between GLP-1 drugs and an increased risk…
A popular class of weight loss and diabetes drugs looks to be safer than feared, at least so far. This week, the Food and Drug Administration announced it hasn’t found compelling evidence that Wegovy, Ozempic, and other GLP-1 drugs can cause suicidal thoughts or behaviors—a concern that first emerged last year. The…
UK regulators are investigating the Ozempic and Saxenda weight loss drugs over reports that patients experienced suicidal and self-harming thoughts while taking the medications. The drugs skyrocketed in popularity in the U.S. as doctors began prescribing them to people who struggled with obesity, but new reports are…
